Osteogenic Cells Derived From Embryonic Stem Cells Produced Bone Nodules in Three-Dimensional Scaffolds

G. R. Chaudhry, 1,* D. Yao, 2 A. Smith, 1 and A. Hussain 1

1Department of Biological Sciences, Oakland University, Rochester, MI 48309, USA
2Department of Mechanical Engineering, Oakland University, Rochester, MI 48309, USA

Received 25 October 2003; revised 27 February 2004; accepted 18 March 2004

An approach for 3D bone tissue generation from embryonic stem (ES) cells was investigated. The ES cells were induced to differentiate into osteogenic precursors, capable of proliferating and subsequently differentiating into bone-forming cells. The differentiated cells and the seeded scaffolds were characterized using von Kossa and Alizarin Red staining, electron microscopy, and RT-PCR analysis. The results demonstrated that ES-derived bone-forming cells attached to and colonized the biocompatible and biodegradable scaffolds. Furthermore, these cells produced bone nodules when grown for 3–4 weeks in mineralization medium containing ascorbic acid and beta-glycerophosphate both in tissue culture plates and in scaffolds. The differentiated cells also expressed osteospecific markers when grown both in the culture plates and in 3D scaffolds. Osteogenic cells expressed alkaline phosphatase, osteocalcin, and osteopontin, but not an ES cell-specific marker, oct-4. These findings suggest that ES cell can be used for in vitro tissue engineering and cultivation of graftable skeletal structures.

INTRODUCTION

Although autogenous bone grafting remains the main choice for treatment of bone fractures, bone defects, and therapeutic arthrodesis, efficacy is limited by donor morbidity and the lack of tissue resource availability [1]. On the other hand, alloplastic materials lack desired properties and consequently result in a high rate of failure [2]. Therefore, there is a great need for renewable sources of materials based on the tissue engineering approach for bone regeneration, repair, and replacement.

Embryonic stem (ES) cells are pluripotent cells derived from the inner cell mass of preimplantation embryos and represent embryonic precursor cells that give rise to any cell type in the embryo [3]. When ES cells are allowed to differentiate in a suspension culture, they form spherical multicellular aggregates, called embryoid bodies (EBs), which have been shown to contain a variety of cell populations [4, 5]. Significant progress has been achieved in inducing murine ES (mES) cells to differentiate into particular types of cells, such as hematopoietic cells [6, 7], cardiomyocytes [8], smooth muscle cells [9, 10], neurons [11, 12, 13, 14], and even organs such as a functional gut-like unit [15] and pancreatic islet-like organization [16]. Specifically, it has been shown that ES cells can differentiate into osteogenic cells under selective culture conditions [17, 18, 19, 20]. The osteogenic cells are capable of in vitro producing extracellular organic matrix of bone collagen 1 and osteocalcin (OC) [17]. The ability of ES cells to in vitro differentiate into a variety of cell types provides novel opportunities to use them for new therapeutic strategies such as cell transplantation and tissue and organ regeneration, replacement, and repair.

The recent identification of osteogenesis-related transcription factors and osteoblast-specific markers has led to a rapid advancement in understanding the process of osteoblast differentiation [21]. Many growth factors and cytokines have been shown to promote the differentiation of osteoblasts, including insulin-like growth factor-1 [22], melatonin [23], and IL-6-related cytokines [24]. Bone morphogenic protein (BMP) family members have been shown to exert particularly strong osteoinductive effects. It was recently found that compounds that are able to upregulate the promoter of BMP 2 result in identification of statins, drugs of the HMG-CoA reductase inhibitor family [25, 26]. One of these drugs, compactin, has shown the potential of enhancing osteogenesis in mES cells [26, 27].

It is believed that most organ cells, including osteoblast or osteoblast-like cells, are anchorage-dependent and require specific environments for growth, which include the presence of a supporting scaffold [28]. This 3D scaffold will provide a supporting frame and act as a template for osteogenesis. In order to permit the ingress of bone cells and nutrients, a porous structure...
with interconnected channels for 3D penetration is crucial. The required characteristics of the material for the scaffold include biocompatibility and biodegradability. Various studies have been carried out to test the attachment and spreading of osteoblast or osteoblast-like cells on porous membranes or 3D scaffolds using collagen, calcium phosphate, poly lactic acid (PLA), and PLA copolymers with glycolide [29, 30, 31, 32, 33, 34, 35]. Particularly, recent work by Wiedmann-Al-Ahmad et al. [29] investigated the seeding and culture of human osteoblast-like cells on several different types of collagen. These previous studies indicated that the seeding and culture of osteoblast-like cells strongly depend on various factors of the scaffold material and its condition, such as topography, chemistry, and surface energy [36, 37].

In the present study, we investigated a new approach for 3D bone tissue generation from stem cells. First, the ES cells were induced to differentiate into osteogenic precursors, capable of proliferating and subsequently differentiating into osteoblasts, bone forming cells. The osteogenic cells were then seeded into a three-dimensional scaffold for in vitro bone tissue generation. The mES cells were used to verify the feasibility of this approach. The experimental result showed that bone-forming cells derived from mES cells can be seeded into a PLA scaffold and subsequently grow and form bone nodules under selective cultivation conditions.

**MATERIAL AND METHODS**

**Scaffold**

OPLA scaffolds [38] from BD Biosciences, Billerica, Mass., were used in the study. The BD OPLA scaffold is a 3D synthetic polymer scaffold that is synthesized from D,DL,L polylactic acid. This material has an open-cell faceted architecture, which is effective for culturing high density cell suspensions [38]. It is of cylindrical shape, with a diameter of 4.2–5.2 mm and a height of 3.9–4.5 mm. The ratio of dry weight to wet weight is 5.2 mg/34 mg. Average pore size ranges from 100–200 µm. The hydration capacity of the scaffold is 30 µL. The modulus of elasticity at 25% strain is 0.92 ± 0.03 Mega Pascal. During in vivo biodegradation, the scaffold is structurally functional for 13 weeks and completely resorbed at the end of 12 months.

**Stem cell culture**

ES cells (D3 [39]), obtained from Dr. K. Sue O’Shea, University of Michigan, Mich.) were maintained on gelatin-coated dishes without feeder cells in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum, 0.1 mM 2-mercaptopethanol (Sigma, St Louis, Mo), 0.1 mM nonessential amino acids (Invitrogen, Carisbad, Calif.), 1 mM sodium pyruvate (Sigma), and 1,000 U/mL of leukemia inhibitory factor (LIF; Chemicon International Inc, Temecula, Calif).

**Differentiation of ES cells to embryoid bodies**

ES cells were cultured as described above. EBs were prepared using the “hanging drop” method [17]. Approximately 1000 cells per 20 µL were incubated on the inverted lid of petri plates for three days. The resulting EBs were then transferred to fresh petri plates and cultured with 10⁻⁷ M cis-retinoic acid for three days with a change of medium each day.

**Differentiation of EBs to osteogenic cells**

To differentiate the EBs to osteogenic cells, the EBs were transferred to gelatin-coated tissue culture plates in ES medium supplemented with ascorbic acid phosphate (50 µg/mL) and β-glycerol phosphate (10 mM) (mineralization medium). The resulting cells were incubated under the same condition for three weeks with a medium change every 2 days.

**Seeding of scaffold**

The EBs were subjected to selective differentiation of osteogenic cells in the mineralization medium as described above and shown to produce bone nodules (see Results). The differentiated cells were treated with trypsin and the scaffolds were seeded as follows.

The scaffolds were placed in six-well tissue culture plates (Fisher Scientific, Hanover, Ill) and seeded with the osteogenic cells derived from EBs (a concentration of 200 µL of 10⁶ cells per mL). The cells were incubated for 0, 2, 4, and 8 hours at 37°C in 5% CO₂ incubator before supplementing with 2.5 mL of the culture medium, and then incubated for 4 weeks with a medium change every 2–3 days. Seeded and unseeded controls included scaffolds seeded with and without ES cells, respectively, and were incubated in the same way in the mineralization medium. The scaffolds were periodically checked under a light microscope and one set for each of the scaffolds including controls (unseeded scaffolds) was sacrificed at intervals of 0, 1, 2, 3, and 4 weeks, and analyzed by scanning electron microscope for the purpose of monitoring cell growth and production of bone nodules as well as expression of specific genetic markers. Simultaneously, six-well culture plates with 100 µL of 10⁶ cells per mL were incubated as above. One set of the wells was sacrificed at intervals of 0, 1, 2, 3, and 4 weeks and analyzed as above. All experiments were run in triplicates.

**Histology**

The osteogenic cells, after growing in the cell culture plates, were analyzed for bone mineral deposition by the von Kossa staining method [40]. Briefly, the cells were rinsed twice with 10 mM phosphate-buffered saline (PBS), and then fixed in 0.2% glutaraldehyde for 1 hour. After rinsing in water, cells were dehydrated in ascending ethanol series (70%, 90%, 100% ethanol) and then air dried. The cells were rehydrated in a descending ethanol series (100%, 90%, 70% ethanol) and water. The plates were then stained with 2% silver nitrate for 1 hour,
Table 1. RT-PCR primers.

| Gene                  | Primer sequence | Product size |
|-----------------------|-----------------|--------------|
| oct-4                 | Sense GCAACTCAGAGGGACCTCCT | 62 bp        |
|                       | Antisense TCTCCAACTCAGGGCATTG |            |
| Alkaline phosphate    | Sense AGGCAGGATTGGACCGG | 138 bp       |
|                       | Antisense TGTAGGTCTGCTCATGGA |        |
| Osteocalcin           | Sense CTTGGTGTCTGACTGGGTGT | 212 bp       |
|                       | Antisense GCCCTCTGACGGA |        |
| Osteopontin           | Sense TCACCTCAGGATGAGCTG | 436 bp       |
|                       | Antisense ACTTGTGGCTCTGATG | |
Production of bone nodules

The osteogenic cells grown for 3 to 4 weeks and subjected to von Kossa staining showed spots of dark brown coloration (Figure 4). Alizarin Red was also used to stain the osteogenic cells (results not shown). ES cells, EBs, or EBs differentiated into cells other than osteogenic cells did not stain under the same conditions. The results shown in Figure 4 suggest that the differentiated osteogenic cells produced bone nodules. Similarly, Phillips et al [27] have reported that osteogenic cells produced extracellular matrix material that was stained by von Kossa staining.

Simultaneously, the differentiated cells derived from EBs were analyzed by TEM. A comparison of ES cells (Figure 3a) and the differentiated cells (Figure 5) shows that the differentiated cell structure has an array of bone nodules in the vicinity of well-developed and extensive amount of mitochondria. Presence of a large number of mitochondria supports the fact that the production of bone nodules is an energy-demanding process.
We investigated the expression of specific molecular markers, such as alkaline phosphatase (ALP), OC, and osteopontin (OP) [27]. The results of the experiments are shown in Figure 7. The oct-4 was expressed only in the ES cells but not in the EB cells. The expression of osteospecific markers, ALP, OP, and OC, was evident in the differentiated cells that produced bone nodules. In some cases, low levels of expression of OC was also detected in messenger RNA that was derived from ES cell (results not shown). The reason for this observation is an unusual splicing event where one to several introns are retained along with the exons. This result is the presence of higher molecular weight transcript that will be expressed in many nonosseous tissues [42].

The ES-cell derived differentiated cells not only colonized the scaffolds but also produced bone nodules as judged by the scanning electron micrography (Figure 6) and von Kossa staining. The RT-PCR analysis of the transcripts of the cells colonizing the scaffold showed expression of osteospecific markers. The mRNA from these cells yielded RT-PCR amplified products of ALP, OC, and OP.

**DISCUSSION**

Totipotent ES cells have been induced to differentiate into a variety of cell types in vitro [6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16]. We present in this study that ES-cell-derived osteoprogenitor cells attached to and colonized the scaffolds. These results show that ES cells can be used for tissue engineering of bone structures/grafts. In vitro grown bone grafts could facilitate skeletal reconstructions in cases involving defects created by tumor resection, injury, and skeletal abnormalities. The grafts developed from the differentiated cells of well-characterized ES cells may provide an alternative to allografts and nonbiodegradable material such as bone cements and metals, especially titanium and ceramics. The use of allografts is disadvantageous due to donor morbidity [43, 44]. The non-biodegradable materials do not promote bone ingrowth [45].

Therefore, tissue engineering of bone structures and their subsequent use as skeletal reconstruction biomaterials, which are bioreabsorbable, biocompatible, not toxic and which allow the bone ingrowth, are desirable. Various studies have been carried out to test the attachment and spreading of osteoblast or osteoblast-like cells on porous membranes or 3D scaffolds using collagen, calcium phosphate, PLA, and PLGA [29, 30, 31, 32, 33, 34, 35]. Particularly, recent work by Wiedmann-Al-Ahmad et al [29] investigated the seeding and culture of human osteoblast-like cells on several different types of collagen. All previous studies indicated that the seeding and culture of osteoblast-like cells strongly depend on various factors of the scaffold material and its condition, such as topography, chemistry, and surface energy [36, 37]. We found that the time interval between seeding of the osteogenic cells into the scaffold and adding growth medium had little
or no effect on colonization, production of bone nodules, and expression of the osteospecific markers. These results are contrary to the previous study [29] reporting that the time interval between seeding osteoblasts and adding culture medium significantly affected the osteoblast proliferation. However, osteoblasts used in this study were derived from patients and were not derived from ES cells as is the case in our study.

The osteogenic cells used for the scaffold seeding study could be characterized as predominantly osteoblast-like or osteoprogenitor since they produced bone nodules and expressed osteospecific markers, ALP, OC, and OP [27]. ALP is an indicator for osteoblast-type cells and OC, an extracellular noncollagenous matrix protein, is exclusively expressed by osteoblasts. However, in our study, no attempt was made to isolate, grow, or determine types of cells in the EB-derived cells. It is likely that the osteogenic cells derived from EBs had multiple types of cell lineage. Therefore, further investigation to enrich and prolong the growth of osteoblast-type cells should be helpful for in vitro tissue engineering and cultivation of graftable skeletal structures.

The use of ES cells as the source for generating graftable skeletal tissues is advantageous compared with existing sources (such as bone marrows) for bone tissue engineering. The supply of autologous tissues and compatible bone-marrow-derived grafts is limited, while ES cells can provide a renewable source for the production of engineered grafts. ES cells can potentially yield compatible grafts on sustained bases or they may be produced on demand.

In conclusion, our study demonstrates that osteogenic cells can be derived from ES cells which can colonize and grow when seeded into the biocompatible and biodegradable scaffolds. Furthermore, these cells expressed osteospecific markers and produced bone nodules when grown both in the culture plates and in 3D scaffolds. Additional improvements in the protocol could allow cultivation of graftable tissues. Further studies with other biomaterials used as scaffolds should be helpful for identifying optimal conditions for in vitro cultivation of graftable osseous structures.

ACKNOWLEDGMENTS

This study was supported by the College of Arts and Sciences, Oakland University. The authors wish to thank Dr K. S. Oshea for the mouse embryonic stem cells and Todd Miller and L. T. N. Dang for the TEM and SEM work.

REFERENCES

[1] Marx RE, Morales MJ. Morbidity from bone harvest in major jaw reconstruction: a randomized trial comparing the lateral anterior and posterior approaches to the ilium. J Oral Maxillofac Surg. 1988;46(3):196–203.

[2] Closer Look-Growing Scandal over TMJ and Jaw Implants. Medical Materials Update, June 1994.

[3] Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from mouse embryos. Nature. 1981;292(5819):154–156.
[4] Robertson EJ. Embryo-derived stem cell lines. In: Robertson EJ ed. Teratocarcinomas and Embryonic Stem Cells: a Practical Approach. 1st ed. Washington, DC: IRL Press; 1987:71–112.

[5] Keller GM. In vitro differentiation of embryonic stem cells. Curr Opin Cell Biol. 1995;7(6):862–869.

[6] Potocnik AJ, Kohler H, Eichmann K. Hematopoiesis in vivo reconstitution potential of subpopulations derived from in vitro differentiated embryonic stem cells. Proc Natl Acad Sci USA. 1997;94 (19):10295–10300.

[7] Ling V, Neben S. In vitro differentiation of embryonic stem cells: immunophenotypic analysis of cultured embryoid bodies. J Cell Physiol. 1997;171(1):104–115.

[8] Klug MG, Soonpaa MH, Koh GY, Field LJ. Genetically selected cardiomyocytes from differentiating embryonic stem cells form stable intracardiac grafts. J Clin Invest. 1996;98(1):216–224.

[9] Ng WA, Doetschman T, Robbins J, Lessard JL. Muscle isoactin expression during in vitro differentiation of murine embryonic stem cells. Pediatr Res. 1997;41(2):285–292.

[10] Drab M, Haller H, Bychkov R, et al. From totipotent embryonic stem cells to spontaneously contracting smooth muscle cells: a retinoic acid and db-cAMP in vitro differentiation model. FASEB J. 1997;11(11):905–915.

[11] Bain G, Kitchens D, Yao M, Huettner JE, Gottlieb DI. Embryonic stem cells express neuronal properties in vitro. Dev Biol. 1995;168(2):342–357.

[12] Brustle O, Jones KN, Learish RD, et al. Embryonic stem cell-derived glial precursors: a source of myelinating transplants. Science. 1999;285(5428):754–756.

[13] McDonald JW, Liu XZ, Qu Y, et al. Transplanted embryonic stem cells survive, differentiate and promote recovery in injured rat spinal cord. Nat Med. 1999;5(12):1410–1412.

[14] Lee SH, Lumelsky N, Studer L, Auerbach JM, McKay RD. Efficient generation of midbrain and hindbrain neurons from mouse embryonic stem cells. Nat Biotechnol. 2000;18(6):675–679.

[15] Yamada T, Yoshikawa M, Takaki M, et al. In vitro functional gut-like organ formation from mouse embryonic stem cells. Stem Cells. 2002;20(20):41–49.

[16] Lumelsky N, Blondel O, Laeng P, Velasco I, Ravin R, McKay R. Differentiation of embryonic stem cells to insulin-secreting structures similar to pancreatic islets. Science. 2001;292(5520):1389–1394.

[17] Buttery LD, Bourne S, Xynos JD, et al. Differentiation of osteoblasts and in vitro bone formation from murine embryonic stem cells. Tissue Eng. 2001;7(1):89–99.

[18] Peng H, Wright V, Usas A, et al. Synergistic enhancement of bone formation and healing by stem cell-expressed VEGF and bone morphogenetic protein-
[33] Kononen M, Hormia M, Kivilahti J, Hautaniemi J, Thesleff I. Effect of surface processing on the attachment, orientation, and proliferation of human gingival fibroblasts on titanium. *J Biomed Mater Res*. 1992;26(10):1325–1341.

[34] Glantz PO. The choice of alloplastic materials for oral implants: does it really matter? *Int J Prosthodont*. 1998;11(5):402–407.

[35] Zeng H, Chittur KK, Lacefield WR. Analysis of bovine serum albumin adsorption on calcium phosphate and titanium surfaces. *Biomaterials*. 1999;20(4):377–384.

[36] Anselme K. Osteoblast adhesion on biomaterials. *Biomaterials*. 2000;21(7):667–681.

[37] Boyan BD, Hummert TW, Dean DD, Schwartz Z. Role of material surfaces in regulating bone and cartilage cell response. *Biomaterials*. 1996;17(2):137–146.

[38] BD™ three dimensional OPLA® Scaffold, guideline for use. Catalog from BD Biosciences.

[39] Galli SJ, Zsebo KM, Geissler EN. The kit ligand, stem cell factor. *Adv Immunol*. 1994;55:1–96.

[40] Humason GL. *Animal Tissue Techniques*. London: Freeman; 1979.

[41] Cooper MS, Hewison M, Stewart PM. Glucocorticoid activity, inactivity and the osteoblast. *J Endocrinol*. 1999;163:159–164.

[42] Jung C, Ou YC, Yeung F, Frierson HF, Jr, Kao C. Osteocalcin is incompletely spliced in non-osseous tissues. *Gene*. 2001;271:143–150.

[43] Ishaug SL, Crane GM, Miller MJ, Yasko AW, Yaszemski MJ, Mikos AG. Bone formation by three-dimensional stromal osteoblast culture in biodegradable polymer scaffolds. *J Biomed Mater Res*. 1997;36(1):17–28.

[44] Crane GM, Ishaug SL, Mikos AG. Bone tissue engineering. *Nat Med*. 1995;1(12):1322–1324.

[45] Yaszemski MJ, Payne RG, Hayes WC, Langer R, Mikos AG. Evolution of bone transplantation: molecular, cellular and tissue strategies to engineer human bone. *Biomaterials*. 1996;17(2):175–185.

* Corresponding author.
E-mail: chaudhry@oakland.edu
Fax: +1 248 370 3586; Tel: +1 248 370 3350